Table 1.
Simulated interventions, deployment, coverage, and efficacy
| Deployment | Efficacy | ||||
|---|---|---|---|---|---|
| Coverage | Timing | Active ingredient/Efficacy mechanism | Resistance | Duration | |
| CM | As in MIS 2016 [41] or 85% |
Jan 2017 |
ACT | 0% | Constant |
| ITN-MRC | 80% |
Jan 2019 |
pyrethroid | 80% | 50% effectively used after 3 years |
| ITN-SNP | 40%, 70% |
Jan 2017–2020 |
pyrethroid resistance | 80% | 50% effectively used after 3 years |
| IRS | 85% |
Sep 2017–2020* |
Actellic 50EC, Bendiocarb | 0% |
3 months (Actellic 50EC) 6 months (Bendiocarb) |
| LSM | 60% |
Setting specific at peak in transmission 2017–2020 |
Reduction of emerging adult mosquitoes | – | 4 months of constant effectiveness |
| IPTsc |
80% 5–16 years |
Jun, Oct 2017–2020 |
Immediate clearance of blood-stage parasites | – | 2 weeks prophylactic effect |
| MDA | 80% |
Jun, Aug, Oct 2017–2020 |
Immediate clearance of blood-stage parasites | – | No prophylactic effect |
* Applying in rotation Bendiocarb and Actellic 50EC, starting with Bendiocarb in 2017